These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29777007)

  • 1. Development of
    Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH
    J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of [
    Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary clinical trial to evaluate
    Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
    EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
    Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
    Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with
    Tolmachev V; Yim CB; Rajander J; Perols A; Karlström AE; Haaparanta-Solin M; Grönroos TJ; Solin O; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():8565802. PubMed ID: 29097939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
    Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of [
    Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
    Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
    Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
    J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
    Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.
    Moreau M; Poty S; Vrigneaud JM; Walker P; Guillemin M; Raguin O; Oudot A; Bernhard C; Goze C; Boschetti F; Collin B; Brunotte F; Denat F
    Dalton Trans; 2017 Oct; 46(42):14659-14668. PubMed ID: 28861553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.